TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer.

BACKGROUND Polymorphisms in the TNF-alpha promoter region have recently been shown to be associated with susceptibility to cervical cancer. Some polymorphisms have been reported to influence transcription for this cytokine. Altered local levels in the cervix may influence an individual's immune response, thereby affecting persistence of human papillomavirus (HPV) 16 infection, a primary etiological factor for cervical cancer. METHODS AND RESULTS The association of 11 TNF-alpha single-nucleotide polymorphisms (SNPs) with susceptibility to HPV16-associated cervical cancer was investigated. Sequencing of the TNF-alpha promoter region confirmed 10 SNPs, and 1 previously unreported SNP (161 bp upstream of the transcriptional start site) was discovered. Microsphere-array flow cytometry-based genotyping was performed on 787 samples from Hispanic and non-Hispanic white women (241 from randomly selected control subjects, 205 from HPV16-positive control subjects, and 341 from HPV16-positive subjects with cervical cancer). The genotype distribution of 3 SNPs (-572, -857, and -863) was significantly different between case subjects and control subjects. Analysis of haplotypes, which were computationally inferred from genotype data, also revealed statistically significant differences in haplotype distribution between case subjects and control subjects. CONCLUSIONS We report new associations between several TNF-alpha SNPs and susceptibility to cervical cancer that support the involvement of the TNF- alpha promoter region in development of cervical cancer.

[1]  L. Abraham,et al.  The −308 tumor necrosis factor-α promoter polymorphism effects transcription , 1997 .

[2]  F. Breedveld,et al.  Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? , 1997, British journal of rheumatology.

[3]  T. Out,et al.  Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. , 2001, Cytokine.

[4]  D. Anderson,et al.  Cytokine induced modulation of MHC class I and class II molecules on human cervical epithelial cells. , 1998, Journal of reproductive immunology.

[5]  M. Feldmann,et al.  Cytokines and anti-cytokine biologicals in autoimmunity: present and future. , 2002, Cytokine & growth factor reviews.

[6]  A. Hamsten,et al.  A Common Functional Polymorphism (C→A Substitution at Position −863) in the Promoter Region of the Tumour Necrosis Factor-α (TNF-α) Gene Associated With Reduced Circulating Levels of TNF-α , 1999 .

[7]  M. Petri,et al.  A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. , 1997, Arthritis and rheumatism.

[8]  K. Tokunaga,et al.  Allele typing of human TNFA 5'-flanking region using polymerase chain reaction-preferential homoduplex formation assay (PCR-PHFA): linkage disequilibrium with HLA class I and class II genes in Japanese. , 1999, Tissue antigens.

[9]  A. Kimura,et al.  Polymorphism of the 5′‐flanking region of the human tumor necrosis factor (TNF)‐α gene in Japanese , 1998 .

[10]  J. Cuzick,et al.  Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women , 2000, British Journal of Cancer.

[11]  M. V. van Krugten,et al.  TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. , 2000, Arthritis and rheumatism.

[12]  F. Wiklund,et al.  Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  M. Carrington,et al.  High-resolution patterns of meiotic recombination across the human major histocompatibility complex. , 2002, American journal of human genetics.

[14]  R. Allen.  Polymorphism of the human TNF-α promoter — random variation or functional diversity? , 1999 .

[15]  P. Posch,et al.  Novel polymorphisms and the definition of promoter ‘alleles’ of the tumor necrosis factor and lymphotoxin α loci: inclusion in HLA haplotypes , 2003, Genes and Immunity.

[16]  D. Kwiatkowski,et al.  Functional Consequences of a Polymorphism Affecting NF-κB p50-p50 Binding to the TNF Promoter Region , 2000, Molecular and Cellular Biology.

[17]  M. Petzl-Erler,et al.  Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  C. Wheeler,et al.  Sample preparation and PCR amplification from paraffin-embedded tissues. , 1994, PCR methods and applications.

[19]  D. Nickerson,et al.  PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. , 1997, Nucleic acids research.

[20]  Kevin Marsh,et al.  A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria , 1999, Nature Genetics.

[21]  K. Tokunaga,et al.  Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA) promoter , 2001, Genes and Immunity.

[22]  S. Cha,et al.  TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. , 2003, Gynecologic oncology.

[23]  Yan P. Yuan,et al.  HGVbase: a human sequence variation database emphasizing data quality and a broad spectrum of data sources , 2002, Nucleic Acids Res..

[24]  Lars Kaderali,et al.  Primer-design for multiplexed genotyping. , 2003, Nucleic acids research.

[25]  M. Béquet-Romero,et al.  Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. , 2000, Biochemical and biophysical research communications.

[26]  Jung-Hwan Yoon,et al.  Association of TNF-α promoter polymorphisms with the clearance of hepatitis B virus infection , 2003 .

[27]  Klaus Pfeffer,et al.  Biological functions of tumor necrosis factor cytokines and their receptors. , 2003, Cytokine & growth factor reviews.

[28]  S. Jabłońska,et al.  Cellular immunity in cutaneous and genital HPV infections. , 1997, Clinics in dermatology.

[29]  G. Strassmann,et al.  Mutational analysis of TNF-alpha gene reveals a regulatory role for the 3'-untranslated region in the genetic predisposition to lupus-like autoimmune disease. , 1996, Journal of immunology.

[30]  P. S. White,et al.  Flow cytometry-based minisequencing: a new platform for high-throughput single-nucleotide polymorphism scoring. , 2000, Genomics.

[31]  M. Newport,et al.  Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. , 1996, The Journal of infectious diseases.

[32]  C. Peyton,et al.  Determinants of genital human papillomavirus detection in a US population. , 2001, The Journal of infectious diseases.

[33]  G. Salles,et al.  Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. , 2002, Blood.

[34]  R. Burk,et al.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. , 1995, Journal of the National Cancer Institute.

[35]  M. Carrington,et al.  Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. , 2001, The Journal of infectious diseases.

[36]  A. Hajeer,et al.  Influence of TNFa gene polymorphisms on TNFa production and disease , 2001 .

[37]  M. Yutsudo,et al.  Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. , 1994, Virology.

[38]  R. Kiessling,et al.  Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. , 2001, Blood.

[39]  D. Hartl,et al.  Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. , 1998, Tissue antigens.

[40]  H. Mcdevitt,et al.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Münger,et al.  The Cytokines Tumor Necrosis Factor-α (TNF-α) and TNF-related Apoptosis-inducing Ligand Differentially Modulate Proliferation and Apoptotic Pathways in Human Keratinocytes Expressing the Human Papillomavirus-16 E7 Oncoprotein* , 2001, The Journal of Biological Chemistry.

[42]  P Green,et al.  Base-calling of automated sequencer traces using phred. II. Error probabilities. , 1998, Genome research.

[43]  A. Cambon-Thomsen,et al.  Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Schneider,et al.  A tumour necrosis factor‐alpha (TNF‐α) promoter polymorphism is associated with chronic hepatitis B infection , 1998 .

[45]  T. Luger,et al.  Autocrine growth limitation of human papillomavirus type 16-harboring keratinocytes by constitutively released tumor necrosis factor-alpha. , 1992, Journal of immunology.

[46]  C. Ware,et al.  TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. , 1998, Journal of immunology.

[47]  Stephen J Iturria,et al.  Host genetic polymorphism analysis in cervical cancer. , 2002, Clinical chemistry.

[48]  D. Kwiatkowski,et al.  Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria , 1994, Nature.

[49]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[50]  L. Villa,et al.  Tumor necrosis factor alpha interferes with the cell cycle of normal and papillomavirus-immortalized human keratinocytes. , 1996, Cancer research.

[51]  A. Hildesheim,et al.  Host and viral genetics and risk of cervical cancer: a review. , 2002, Virus research.

[52]  A. Hill.  Immunogenetics and genomics , 2001, The Lancet.

[53]  A. Hajeer,et al.  TNF‐α gene polymorphism: Clinical and biological implications , 2000 .

[54]  Jacques Ferlay,et al.  Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.

[55]  P. Green,et al.  Base-calling of automated sequencer traces using phred. I. Accuracy assessment. , 1998, Genome research.

[56]  K. Suk,et al.  Interferon gamma (IFNgamma ) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. , 2001, The Journal of biological chemistry.

[57]  J. Chun,et al.  The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. , 2001, Cancer letters.

[58]  F. Pociot,et al.  Cytokine gene polymorphism in human disease: on-line databases, Supplement 2 , 2002, Genes and Immunity.

[59]  F. O'Gara,et al.  Tumour necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families , 2001, Genes and Immunity.

[60]  C. Peyton,et al.  Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method , 1998, Journal of Clinical Microbiology.

[61]  Zhaohui S. Qin,et al.  Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. , 2002, American journal of human genetics.

[62]  B. Brumback,et al.  Human leukocyte antigen class II and cervical cancer risk: a population-based study. , 2002, The Journal of infectious diseases.